Sermorelin vs CJC-1295 (No DAC)
How do Sermorelin and CJC-1295 (No DAC) compare for Growth Hormone Axis research? Side-by-side evidence, molecular profile, EU legal status and COA-verified supplier prices — never dosing advice.
At a glance
Sermorelin
CJC-1295 (No DAC)
Which fits which research target?
Both Sermorelin and CJC-1295 (No DAC) sit within Growth Hormone Axis research but are studied for different primary signals. Neither is an approved medicine — compare the evidence, not marketing claims.
What the research shows
Sermorelin
CJC-1295 (No DAC)
Compare prices across EU suppliers
Compare Sermorelin across EU suppliers
6 EU vendors · COA · from €31.45
Compare CJC-1295 (No DAC) across EU suppliers
7 EU vendors · COA · from €23.89
Frequently asked questions
Is Sermorelin or CJC-1295 (No DAC) better? ▾
Neither is an approved medicine, and “better” depends on the research target. Sermorelin is most associated with GH/IGF-1 elevation, while CJC-1295 (No DAC) is studied for Pulsatile GH release. Compare the evidence tiers and COA-verified EU pricing above rather than assuming one is superior. This is not a usage recommendation.
Why compare Sermorelin and CJC-1295 (No DAC)? ▾
Both are studied within Growth Hormone Axis research through different mechanisms, so researchers often weigh them against each other. This page sets their evidence, molecular profile, EU legal status and supplier pricing side by side.
Which is cheaper in the EU, Sermorelin or CJC-1295 (No DAC)? ▾
Prices vary by supplier, vial size and COA status. Sermorelin is listed from €31.45 across 6 COA-verified EU vendors; CJC-1295 (No DAC) from €23.89 across 7. Open the price pages above to compare current listings — nobody pays us for placement.